KR20220142471A - 폴리펩타이드 및 그 용도 - Google Patents

폴리펩타이드 및 그 용도 Download PDF

Info

Publication number
KR20220142471A
KR20220142471A KR1020227031325A KR20227031325A KR20220142471A KR 20220142471 A KR20220142471 A KR 20220142471A KR 1020227031325 A KR1020227031325 A KR 1020227031325A KR 20227031325 A KR20227031325 A KR 20227031325A KR 20220142471 A KR20220142471 A KR 20220142471A
Authority
KR
South Korea
Prior art keywords
leu
val
ala
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227031325A
Other languages
English (en)
Korean (ko)
Inventor
넬 피 킹
칼 월키
징 양 왕
브룩 피알라
데이비드 비슬러
알렉산드라 씨 왈스
우나 나테르만
Original Assignee
유니버시티 오브 워싱턴
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 워싱턴 filed Critical 유니버시티 오브 워싱턴
Publication of KR20220142471A publication Critical patent/KR20220142471A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
KR1020227031325A 2020-02-14 2021-02-12 폴리펩타이드 및 그 용도 Pending KR20220142471A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US62/977,036 2020-02-14
PCT/US2021/017856 WO2021163481A1 (en) 2020-02-14 2021-02-12 Polypeptides and their use

Publications (1)

Publication Number Publication Date
KR20220142471A true KR20220142471A (ko) 2022-10-21

Family

ID=77292738

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031325A Pending KR20220142471A (ko) 2020-02-14 2021-02-12 폴리펩타이드 및 그 용도

Country Status (10)

Country Link
US (1) US20230075095A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103586A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023513592A (cg-RX-API-DMAC7.html)
KR (1) KR20220142471A (cg-RX-API-DMAC7.html)
AU (1) AU2021220958A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016197A2 (cg-RX-API-DMAC7.html)
CL (2) CL2022002215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011395A2 (cg-RX-API-DMAC7.html)
PE (1) PE20230486A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021163481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
US20250215055A1 (en) * 2022-04-07 2025-07-03 University Of Washington Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
AU2024265411A1 (en) 2023-05-01 2025-11-06 University Of Washington Pre-fusion-stabilized cmv gb protein nanostructures
AR133824A1 (es) * 2023-09-15 2025-11-05 Icosavax Inc Proteínas virales y nanoestructuras y usos de estas
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025207938A1 (en) * 2024-03-29 2025-10-02 University Of Washington Nucleic acid vaccines against coccidioidomycosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568788A1 (en) * 2004-06-16 2005-12-29 Dsm Ip Assets B.V. Production of polypeptides by improved secretion
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016199898A1 (ja) * 2015-06-10 2016-12-15 公立大学法人 富山県立大学 活性型変異酵素の製造方法および新規活性型変異酵素、並びに可溶性化変異タンパク質の製造方法
WO2018047856A1 (ja) * 2016-09-06 2018-03-15 学校法人慶應義塾 融合タンパク質、構造体、捕集剤、捕集する方法、dna、及びベクター
US11866699B2 (en) * 2017-02-10 2024-01-09 University Of Washington Genome editing reagents and their use
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗
AU2019285048B2 (en) * 2018-06-13 2023-06-08 The Scripps Research Institute Nanoparticle vaccines with novel structural components
FR3083804B1 (fr) * 2018-07-13 2022-08-12 Institut Nat Des Sciences Appliquees De Toulouse Micro-organismes et procede pour la production d'acide glycolique a partir de pentoses et d'hexoses

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
Air GM. Influenza virus antigenicity and broadly neutralizing epitopes. Curr Opin Virol. 2015;11:113-21.
Bhaskar A, Chawla M, Mehta M, Parikh P, Chandra P, Bhave D, Kumar D, Carroll KS, Singh A. Reengineering Redox Sensitive GFP to Measure Mycothiol Redox Potential of Mycobacterium tuberculosis during Infection. PLoS Pathog. 2014;10(1).
Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol. 2000;328(1999):430-44.
Braakman I, Hebert DN. Protein Folding in the Endoplasmic Reticulum. Compr Biotechnol Second Ed. 2011;1:217-27.
Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol. 2016;34(1):635-59.
Butterfield GL, Lajoie MJ, Gustafson HH, Sellers DL, Nattermann U, Ellis D, Bale JB, Ke S, Lenz GH, Yehdego A, Ravichandran R, Pun SH, King NP, Baker D. Evolution of a designed protein assembly encapsulating its own RNA genome. Nature. 2017;552(7685):415-20.
Cherf GM, Cochran JR. Applications of yeast surface display for protein engineering. Methods Mol Biol. 2015;1319:155-75.
Chuang KH, Hsieh YC, Chiang IS, Chuang CH, Kao CH, Cheng TC, Wang YT, Lin WW, Chen BM, Roffler SR, Huang MY, Cheng TL. High-throughput sorting of the highest producing cell via a transiently protein-anchored system. PLoS One. 2014;9(7):1-7.
Cymer F, Von Heijne G, White SH. Mechanisms of integral membrane protein insertion and folding. J Mol Biol. 2015;427(5):999-1022.
De Felipe P, Luke GA, Hughes LE, Gani D, Halpin C, Ryan MD. E unum pluribus: Multiple proteins from a self-processing polyprotein. Trends Biotechnol. 2006;24(2):68-75.
Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. 2014;6(6):708-20.
Denks K, Vogt A, Sachelaru I, Petriman NA, Kudva R, Koch HG. The Sec translocon mediated protein transport in prokaryotes and eukaryotes. Vol. 31, Molecular Membrane Biology. 2014. p. 58-84.
Donnelly MLL, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD. Analysis of the aphthovirus 2A/2B polyprotein "cleavage" mechanism indicates not a proteolytic reaction, but a novel translational effect: A putative ribosomal "skip". J Gen Virol. 2001;82(5):1013-25.
Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, Long CA, Seder RA. Malaria Vaccines: Recent Advances and New Horizons. Cell Host Microbe. 2018;24(1):43-56.
Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science (80- ). 2002;296(5577):2354-60.
Graham BS, Gilman MSA, McLellan JS. Structure-Based Vaccine Antigen Design. Annu Rev Med. 2019;70(1):91-104.
Harcus TE, Gluckman M, Pontzer H, Raichlen DA, Marlowe FW, Siegfried WR, Macdonald IAW, Call J, Fischer J, Stryjewski KF, Quader S, Sorenson MD, Boogert N, Davies N, Flower T, Jamie G, Magrath R, Rendall D, Ruxton G, Sorensen M, Wood B, David C, Bale JB, Gonen S, Liu Y, Sheffler W, Ellis D, Thomas C, Cascio D, Yeates TO, Gonen T, King NP, Baker D. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science (80- ). 2016;353(6297):389-95.
Hessa T, Kim H, Bihlmaier K, Lundin C, Boekel J, Andersson H, Nilsson IM, White SH, Von Heijne G. Recognition of transmembrane helices by the endoplasmic reticulum translocon. Nature. 2005;433(7024):377-81.
Hessa T, Meindl-Beinker NM, Bernsel A, Kim H, Sato Y, Lerch-Bader M, Nilsson I, White SH, Von Heijne G. Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature. 2007 Dec 13;450(7172):1026-30.
Hsia Y, Bale JB, Gonen S, Shi D, Sheffler W, Fong KK, Nattermann U, Xu C, Huang PS, Ravichandran R, Yi S, Davis TN, Gonen T, King NP, Baker D. Design of a hyperstable 60-subunit protein icosahedron. Nature. 2016 Jul 15;535(7610):136-9.
Huang PS, Boyken SE, Baker D. The coming of age of de novo protein design. Nature. 2016;537(7620):320-7.
Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat Immunol. 2019;20(3):362-72.
Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JRR, Rao SS, Kong WP, Wang L, Nabel GJ. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499(7456):102-6.
King NP, Bale JB, Sheffler W, McNamara DE, Gonen S, Gonen T, Yeates TO, Baker D. Accurate design of co-assembling multi-component protein nanomaterials. Nature. 2014;510(7503):103-8.
Liu Z, Chen O, Wall JBJ, Zheng M, Zhou Y, Wang L, Ruth Vaseghi H, Qian L, Liu J. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep. 2017;7(1):1-9.
Lopez-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J. 2016;14:58-68.
Marcandalli J, Fiala B, Ols S, Perotti M, de van der Schueren W, Snijder J, Hodge E, Benhaim M, Ravichandran R, Carter L, Sheffler W, Brunner L, Lawrenz M, Dubois P, Lanzavecchia A, Sallusto F, Lee KK, Veesler D, Correnti CE, Stewart LJ, Baker D, Lore K, Perez L, King NP. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell. 2019;176(6):1420-1431.e17.
Morein B, Simons K. Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. Vaccine. 1985;3(2):83-93.
Moyle PM, Toth I. Modern Subunit Vaccines: Development, Components, and Research Opportunities. ChemMedChem. 2013 Mar;8(3):360-76.
Nishikawa I, Nakajima Y, Ito M, Fukuchi S, Homma K, Nishikawa K. Computational prediction of O-linked glycosylation sites that preferentially map on intrinsically disordered regions of extracellular proteins. Int J Mol Sci. 2010;11(12):4991-5008.
Nyathi Y, Wilkinson BM, Pool MR. Co-translational targeting and translocation of proteins to the endoplasmic reticulum. Biochim Biophys Acta - Mol Cell Res. 2013;1833(11):2392-402.
Pagny S, Cabanes-Macheteau M, Gillikin JW, Leborgne-Castel N, Lerouge P, Boston RS, Faye L, Gomord V. Protein recycling from the Golgi apparatus to the endoplasmic reticulum in plants and its minor contribution to calreticulin retention. Plant Cell. 2000;12(5):739-55.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-79.
Patil SU, Shreffler WG. Novel vaccines: Technology and development. J Allergy Clin Immunol. 2019;143(3):844-51.
Pica N, Palese P. Toward a Universal Influenza Virus Vaccine: Prospects and Challenges. Annu Rev Med. 2013;64(1):189-202.
Pinder CL, Kratochvil S, Cizmeci D, Muir L, Guo Y, Shattock RJ, McKay PF. Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay. J Immunol. 2017;199(12):4180-8.
Plotkin S. Vaccines: past , present and future Early successes. Nat Med. 2005;11(4):5-11.
Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011;12(6):509-17.
Ra J-S, Shin H-H, Kang S, Do Y. Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development. Clin Exp Vaccine Res. 2014;3(2):227.
Remacle AG, Shiryaev SA, Oh ES, Cieplak P, Srinivasan A, Wei G, Liddington RC, Ratnikov BI, Parent A, Desjardins R, Day R, Smith JW, Lebl M, Strongin AY. Substrate cleavage analysis of furin and related proprotein convertases: A comparative study. J Biol Chem. 2008;283(30):20897-906.
Ryan MD, King AMQ, Thomas GP. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol. 1991;72(11):2727-32.
Thomas G. Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3(10):753-66.
Vartak A, Sucheck SJ. Recent advances in subunit vaccine carriers. Vaccines. 2016;4(2):1-18.
Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A. 2012;109(12).
Zandi R, Reguera D, Bruinsma RF, Gelbart WM, Rudnick J. Origin of icosahedral symmetry in viruses. Proc Natl Acad Sci U S A. 2004;101(44):15556-60.
Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg APJ. Nanoparticle vaccines. Vaccine. 2014;32(3):327-37.

Also Published As

Publication number Publication date
JP2023513592A (ja) 2023-03-31
EP4103586A1 (en) 2022-12-21
PE20230486A1 (es) 2023-03-21
WO2021163481A1 (en) 2021-08-19
CL2022002215A1 (es) 2023-05-05
AU2021220958A1 (en) 2022-09-01
EP4103586A4 (en) 2024-05-15
US20230075095A1 (en) 2023-03-09
CO2022011395A2 (es) 2023-01-16
BR112022016197A2 (pt) 2022-10-25
CL2025002147A1 (es) 2026-03-06

Similar Documents

Publication Publication Date Title
US20230075095A1 (en) Polypeptides and their use
US11759514B2 (en) Stabilized pre-fusion RSV F proteins
KR20160002938A (ko) 안정화된 가용성 예비융합 rsv f 폴리펩타이드
Salzer et al. Single‐dose immunisation with a multimerised SARS‐CoV‐2 receptor binding domain (RBD) induces an enhanced and protective response in mice
Li et al. Identification and CRISPR/Cas9 inactivation of the C1s protease responsible for proteolysis of recombinant proteins produced in CHO cells
Young et al. A platform technology for generating subunit vaccines against diverse viral pathogens
KR20230009445A (ko) 안정화된 코로나바이러스 스파이크 단백질 융합 단백질
AU2023235493A1 (en) Improved igg-degrading enzymes and methods of use thereof
Dalvie et al. Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
Argentinian AntiCovid Consortium anticovid. arg@ gmail. com Berguer Paula M. 2 3 Blaustein Matías 2 4 5 Bredeston Luis M. 6 7 Craig Patricio O. 8 9 D’Alessio Cecilia 2 4 5 Elias Fernanda 10 Farré Paola C. 11 Fernández Natalia B. 2 4 5 Gentili Hernán G. 4 5 Gándola Yamila B. 4 5 Gasulla Javier 4 5 12 Gudesblat Gustavo E. 2 4 5 Herrera María G. 2 4 5 Ibañez Lorena I. 2 13 Idrovo-Hidalgo Tommy 4 5 Nadra Alejandro D. 2 4 5 Noseda Diego G. 14 Paván Carlos H. 2 15 Pavan María F. 2 13 Pignataro María F. 4 5 7 Roman Ernesto A. 6 8 Ruberto Lucas AM 16 17 18 Rubinstein Natalia 2 4 5 Sanchez María V. 19 Santos Javier 2 4 5 8 Wetzler Diana E. 8 9 Zelada Alicia M. 5 20 Covalent coupling of Spike’s receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2
CN118076646A (zh) 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用
US20220041650A1 (en) Purification method for recombinant proteins and nanoparticles
US11618771B2 (en) Covalently fused viral coat proteins for the display of target molecules
WO2022177990A2 (en) Modified sars-cov-2 spike polypeptides and nanoparticles thereof
EP3076999B1 (en) Recombinant respiratory syncytial virus g protein fragments
US9771395B2 (en) Enhanced influenza hemagglutinin binders
Liu et al. Effect and mechanism of C-terminal cysteine on the properties of HEV p222 protein
Jitender et al. A broadly protective CHO cell expressed recombinant spike protein subunit vaccine (IMT-CVAX) against SARS-CoV-2
US20260132171A1 (en) Pre-fusion-stabilized cmv gb protein nanostructures
US20250215055A1 (en) Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery
Zhang et al. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent
Parsons-Dyhrberg Development of a recombinant measles haemagglutinin antigenic bait to enable generation of neutralising monoclonal antibodies for prophylaxis of measles virus infection
Manuel-Cabrera et al. SHORT REPORT Open Access
CN120202213A (zh) 乙型流感病毒疫苗及其用途
HK40000138A (en) Stabilized pre-fusion rsv f proteins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000